Baseline demographic and clinical characteristics of patients with or without MACE at 30 days
. | With 30-day MACE, n = 48 . | Without 30-day MACE, n = 108 . | P . |
|---|---|---|---|
| Age, y, mean ± SD | 64 ± 12 | 65 ± 12 | .62 |
| Aged 80 y, n (%) | 4 (8.3) | 12 (11) | .6 |
| Male, n (%) | 37 (77) | 73 (68) | .23 |
| Ethnicity, n (%) | |||
| White | 29 (60) | 64 (59) | .51 |
| Indo-Asians | 19 (40) | 39 (36) | |
| BMI, kg/m2, mean ± SD | 27 ± 3.8 | 27 ± 4.7 | .97 |
| Active smoker, n (%) | 16 (33) | 38 (35) | .82 |
| Family history of CHD, n (%) | 5 (10) | 13 (12) | .77 |
| Prior history | |||
| AMI, n (%) | 9 (19) | 23 (21) | .72 |
| PCI, n (%) | 1 (2) | 4 (4) | .69 |
| CABG, n (%) | 2 (4) | 13 (12) | .15 |
| Diabetes, n (%) | 11 (23) | 32 (30) | .39 |
| Hypertension, n (%) | 22 (49) | 48 (44) | .87 |
| Dyslipidemia, n (%) | 13 (27) | 32 (30) | .75 |
| Heart failure, n (%) | 4 (8) | 5 (5) | .36 |
| Angina, n (%) | 9 (19) | 25 (23) | .54 |
| Stroke, n (%) | 2 (4.2) | 5 (4.6) | .89 |
| Clinical parameters | |||
| Heart rate, bpm, mean ± SD | 81 ± 14 | 77 ± 14 | .14 |
| Systolic BP, mm Hg, mean ± SD | 128 ± 19 | 133 ± 17 | .051 |
| Killip class 2, n (%) | 15 (31) | 23 (21) | .18 |
| Baseline blood tests | |||
| Cholesterol, mmol/L, mean ± SD | 5.78 ± 0.8 | 5.7 ± 1.0 | .64 |
| HDL-C, mmol/L, mean ± SD | 1.0 ± 0.14 | 1.0 ± 0.13 | .47 |
| Creatinine, μmol/L, mean ± SD | 92 ± 31 | 88 ± 18 | .36 |
| Glucose, mmol/L, mean ± SD | 7.3 ± 2.6 | 7.4 ± 3.0 | .84 |
| Main ischemic area | |||
| Anterior, n (%) | 34 (71) | 65 (60) | .28 |
| Inferior, n (%) | 9 (21) | 36 (33) | |
| Lateral, n (%) | 4 (8.3) | 7 (6.5) | |
| TIMI risk score for | |||
| STEMI, mean ± SD | 4.4 ± 1.5 | 3.2 ± 2.1 | .023 |
| Non-STEMI/UAP, mean ± SD | 4.3 ± 0.9 | 3.7 ± 1.5 | .02 |
. | With 30-day MACE, n = 48 . | Without 30-day MACE, n = 108 . | P . |
|---|---|---|---|
| Age, y, mean ± SD | 64 ± 12 | 65 ± 12 | .62 |
| Aged 80 y, n (%) | 4 (8.3) | 12 (11) | .6 |
| Male, n (%) | 37 (77) | 73 (68) | .23 |
| Ethnicity, n (%) | |||
| White | 29 (60) | 64 (59) | .51 |
| Indo-Asians | 19 (40) | 39 (36) | |
| BMI, kg/m2, mean ± SD | 27 ± 3.8 | 27 ± 4.7 | .97 |
| Active smoker, n (%) | 16 (33) | 38 (35) | .82 |
| Family history of CHD, n (%) | 5 (10) | 13 (12) | .77 |
| Prior history | |||
| AMI, n (%) | 9 (19) | 23 (21) | .72 |
| PCI, n (%) | 1 (2) | 4 (4) | .69 |
| CABG, n (%) | 2 (4) | 13 (12) | .15 |
| Diabetes, n (%) | 11 (23) | 32 (30) | .39 |
| Hypertension, n (%) | 22 (49) | 48 (44) | .87 |
| Dyslipidemia, n (%) | 13 (27) | 32 (30) | .75 |
| Heart failure, n (%) | 4 (8) | 5 (5) | .36 |
| Angina, n (%) | 9 (19) | 25 (23) | .54 |
| Stroke, n (%) | 2 (4.2) | 5 (4.6) | .89 |
| Clinical parameters | |||
| Heart rate, bpm, mean ± SD | 81 ± 14 | 77 ± 14 | .14 |
| Systolic BP, mm Hg, mean ± SD | 128 ± 19 | 133 ± 17 | .051 |
| Killip class 2, n (%) | 15 (31) | 23 (21) | .18 |
| Baseline blood tests | |||
| Cholesterol, mmol/L, mean ± SD | 5.78 ± 0.8 | 5.7 ± 1.0 | .64 |
| HDL-C, mmol/L, mean ± SD | 1.0 ± 0.14 | 1.0 ± 0.13 | .47 |
| Creatinine, μmol/L, mean ± SD | 92 ± 31 | 88 ± 18 | .36 |
| Glucose, mmol/L, mean ± SD | 7.3 ± 2.6 | 7.4 ± 3.0 | .84 |
| Main ischemic area | |||
| Anterior, n (%) | 34 (71) | 65 (60) | .28 |
| Inferior, n (%) | 9 (21) | 36 (33) | |
| Lateral, n (%) | 4 (8.3) | 7 (6.5) | |
| TIMI risk score for | |||
| STEMI, mean ± SD | 4.4 ± 1.5 | 3.2 ± 2.1 | .023 |
| Non-STEMI/UAP, mean ± SD | 4.3 ± 0.9 | 3.7 ± 1.5 | .02 |
MACE indicates major adverse cardiovascular events; BMI, body mass index; HDL-C, high density lipoprotein cholesterol; STEMI, ST-segment elevation myocardial infarction; UAP, unstable angina pectoris; CHD, coronary heart disease; TIMI, thrombolysis in myocardial infarction; CABG, coronary artery bypass grating; PCI, percutaneous coronary intervention; BP, blood pressure; AMI, acute myocardial infarction.